FDA-approved belzutifan + lenvatinib combo reshapes second-line kidney cancer treatment

The FDA's September 2026 approval of belzutifan (Welireg) plus lenvatinib (Lenvima) has established a new second-line standard of care for adults with advanced clear cell renal cell carcinoma (ccRCC) following PD-1 or PD-L1 inhibitor therapy. The decision was backed by the phase 3 LITESPARK-011 trial, which randomized 747 patients to the combination or cabozantinib monotherapy. The combo outperformed cabozantinib on key efficacy measures, including a notably higher objective response rate (~53% vs. 40%) and a nearly doubled duration of response.

Oncologist Daniel Heng, MD, notes that while the approval is a major step forward — pushing response rates closer to 50% compared to the historical 20–30% benchmark — clinicians should not let second-line options drive first-line treatment decisions. He also cautions against re-using lenvatinib in patients who already received it in the first-line setting.

By the Numbers:

• Median PFS: 14.8 months (belzutifan + lenvatinib) vs. 10.8 months (cabozantinib)
• Median OS: 33.7 months vs. 28.6 months (not statistically significant)
• ORR: 53.1% vs. 40.2%
• Median duration of response: 22.0 months vs. 11.9 months
• Serious adverse events: 51.6% in the combination arm vs. 43.9% with cabozantinib

Why it matters: This approval gives oncologists a powerful new second-line option for advanced kidney cancer, with response rates and durability that significantly exceed prior benchmarks — though managing side effects like anemia and hypoxia will require careful monitoring.